The Chikungunya virus (CHIKV) is an emerging mosquito-borne virus in the tropics and Southern Europe. In Latin America, CHIKV was introduced in 2013, infecting millions of people. CHIKV infection frequently leads to severe acute symptoms and to chronic sequelae, sometimes including debilitating arthralgia, in about 45% of patients. Specific treatment and robust biomarkers to predict chronic courses in patients are not available. Relying on a unique clinical cohort containing hundreds of longitudinally sampled patients from Brazil, the CHIKAmark project will examine 680 cumulative parameters through a combination of omics approaches, clinical and virological work to investigate CHIKV pathogenesis and establish biomarkers allowing prioritization of CHIKV patients for preventive treatment.

Here you can find further information.